Novartis Has Proof Of Concept For New R&D Model, And NMEs To Show It
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novartis showed off its new drug pipeline for the first time in three years Nov. 19, but the R&D day was as much about vindicating the novel research strategy it rolled out in 2002 as it was previewing the work in process.
You may also be interested in...
Novartis Brings “Disruptive Innovation” To Clinical Trials
Having reinvigorated its model for early R&D, the company is looking to re-envision the clinical trial process, with initiatives aimed at improving patient selection based on molecular information, clinical trial recruitment and monitoring. A partnership with Walgreens aims to move trials out of tertiary care centers and into pharmacies.
Novartis Brings “Disruptive Innovation” To Clinical Trials
Having reinvigorated its model for early R&D, the company is looking to re-envision the clinical trial process, with initiatives aimed at improving patient selection based on molecular information, clinical trial recruitment and monitoring. A partnership with Walgreens aims to move trials out of tertiary care centers and into pharmacies.
Sidebar: Biologics In The Spotlight: Novartis’ Canakinumab
Novartis' entry among the BLAs with a 2009 user fee goal, canakinumab, well illustrates the company's approach to biologics through the six-year-old Novartis Institute for Biomedical Research.